Sarepta Therapeutics (SRPT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Research Workspace
Put SRPT beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — Achieve profitability and cash-flow positivity in 2026: Q2 FY26 net margin -1.2% vs target >0%.
View ThesisRevenue is contracting — down about 20% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on capital allocation, margins, the balance sheet.
View ManagementExpectations look high — what the market is pricing in runs ahead of what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 39% in its worst 12-month stretch.
View RiskSarepta Therapeutics must achieve profitability and cash-flow positivity in 2026 to justify its price. Recent financial performance is strong, with a Q2 FY26 earnings beat. The stock trades at 1.2× price-to-sales versus an 11.4× peer median, indicating the market prices in more growth than forecast. The primary risk is that the company reported a Q2 FY26 net margin of -1.2%, below the target of greater than 0%. Peer multiples imply a price about 5% below where it trades. The thesis has broken.
Trailing returns as of 2026-09-04. SRPT is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 24 analysts currently covering SRPT (as of Sep 2026).
Based on 4 Wall Street analysts offering 12-month price targets for SRPT in the last 4 months.
Continue this research
Compare SRPT with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| SRPT Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across our valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No fair value published
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
This applies to all three horizons. The trailing multiples, peer comparison, and quality and trajectory reads on this page are unaffected. Names move in and out of this state day to day as the methods converge or diverge. Method agreement on this name is low.
Below average on quality vs scored peers
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put SRPT next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
FDA acceptance could enhance revenue potential for DMD therapies.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $22.50
The last 12 months of price, then the range of analyst 12-month targets from today’s $22.50.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Achieve profitability and cash-flow positivity in 2026
Outlining priorities supports profitability goal.
Advances: Reiterate FY 2026 revenue guidance of $1.2 - $1.4 billion
Importance of Elevidys aligns with revenue guidance.